| Simone R Hampton, MD | |
|
611 W Park St, Urbana, IL 61801-2529 | |
| (217) 383-3170 | |
| (217) 383-7650 |
| Full Name | Simone R Hampton |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 611 W Park St, Urbana, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033184247 | NPI | - | NPPES |
| 036108253 | Medicaid | IL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 036108253 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Carle Foundation Hospital | Urbana, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carle Health Care Incorporated | 3577515774 | 808 |
News Archive
By attaching specialized molecules to the backbone of DNA, researchers have made it easier to detect rare molecules associated with early disease.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
The scientist whose discoveries led to the first drug approved for metastatic melanoma by "treating the immune system, not the cancer," also is the first to receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology.
The year 2009 will be remembered as a year of many firsts for lupus, including the first successful phase III clinical trial of a potential new treatment for lupus, the launch of the first-ever Ad Council public awareness campaign for lupus, and the first comprehensive report on the barriers to lupus drug development. And it appears there are no signs of any slowing of momentum as we enter the New Year.
› Verified 1 days ago
| Entity Name | Carle Health Care Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154653947 PECOS PAC ID: 3577515774 Enrollment ID: O20100513000829 |
News Archive
By attaching specialized molecules to the backbone of DNA, researchers have made it easier to detect rare molecules associated with early disease.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
The scientist whose discoveries led to the first drug approved for metastatic melanoma by "treating the immune system, not the cancer," also is the first to receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology.
The year 2009 will be remembered as a year of many firsts for lupus, including the first successful phase III clinical trial of a potential new treatment for lupus, the launch of the first-ever Ad Council public awareness campaign for lupus, and the first comprehensive report on the barriers to lupus drug development. And it appears there are no signs of any slowing of momentum as we enter the New Year.
› Verified 1 days ago
| Entity Name | Promise Healthcare Nfp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578821005 PECOS PAC ID: 6103071345 Enrollment ID: O20130219000476 |
News Archive
By attaching specialized molecules to the backbone of DNA, researchers have made it easier to detect rare molecules associated with early disease.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
The scientist whose discoveries led to the first drug approved for metastatic melanoma by "treating the immune system, not the cancer," also is the first to receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology.
The year 2009 will be remembered as a year of many firsts for lupus, including the first successful phase III clinical trial of a potential new treatment for lupus, the launch of the first-ever Ad Council public awareness campaign for lupus, and the first comprehensive report on the barriers to lupus drug development. And it appears there are no signs of any slowing of momentum as we enter the New Year.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Simone R Hampton, MD 611 W Park St, Urbana, IL 61801-2529 Ph: (217) 383-6792 | Simone R Hampton, MD 611 W Park St, Urbana, IL 61801-2529 Ph: (217) 383-3170 |
News Archive
By attaching specialized molecules to the backbone of DNA, researchers have made it easier to detect rare molecules associated with early disease.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
The scientist whose discoveries led to the first drug approved for metastatic melanoma by "treating the immune system, not the cancer," also is the first to receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology.
The year 2009 will be remembered as a year of many firsts for lupus, including the first successful phase III clinical trial of a potential new treatment for lupus, the launch of the first-ever Ad Council public awareness campaign for lupus, and the first comprehensive report on the barriers to lupus drug development. And it appears there are no signs of any slowing of momentum as we enter the New Year.
› Verified 1 days ago
Anuja Bedi, D.O, M.P.H Family Medicine Medicare: Medicare Enrolled Practice Location: 611 W Park St, Urbana, IL 61801 Phone: 217-383-3311 | |
Timtim Apperson, APRN Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 611 W Park St, Urbana, IL 61801 Phone: 217-954-2805 | |
Sharon L. Moy, D.O Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1109 S Lincoln Ave, Urbana, IL 61801 Phone: 217-244-5324 | |
Manada Khaing, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 611 W Park St, Urbana, IL 61801 Phone: 217-383-3311 | |
Stephen M Rudawski, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 611 W. Park St., Urbana, IL 61801 Phone: 217-383-3170 Fax: 217-383-7650 | |
Christian E Wagner, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1818 E Windsor Rd, Urbana, IL 61802 Phone: 217-255-9670 Fax: 217-255-9650 |